Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Miehsler, W; Novacek, G; Wenzl, H; Vogelsang, H; Knoflach, P; Kaser, A; Dejaco, C; Petritsch, W; Kapitan, M; Maier, H; Graninger, W; Tilg, H; Reinisch, W; Austrian Society of Gastroenterology and Hepatology.
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
J Crohns Colitis. 2010; 4(3):221-256
Doi: 10.1016/j.crohns.2009.12.001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Dejaco Christian
- Graninger Winfried
- Kapitan Magdalena
- Petritsch Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Infliximab (IFX) has tremendously enriched the therapy of inflammatory bowel diseases (IBD) and other immune mediated diseases. Although the efficacy of IFX was undoubtedly proven during the last decade numerous publications have also caused various safety concerns. To summarize the immense information concerning adverse events and safety issues the Austrian Society of Gastroenterology and Hepatology launched this evidence based consensus on the safe use of IFX which covers the following topics: infusion reactions and immunogenicity, skin reactions, opportunistic infections (including tuberculosis), non-opportunistic infections (bacterial and viral), vaccination, neurological complications, hepatotoxicity, congestive heart failure, haematological side effects, intestinal strictures, stenosis and bowel obstruction (SSO), concomitant medication, malignancy and lymphoma, IFX in the elderly and the young, mortality, fertility, pregnancy and breast feeding. To make the vast amount of information practicable for routine application the consensus was finally condensed into a checklist for a safe use of IFX which consists of two parts: issues to be addressed prior to anti-TNF therapy and issues to be addressed during maintenance. Both parts are further divided into obligatory and facultative items. Copyright © 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Anti-Inflammatory Agents - adverse effects
- Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - contraindications
- Breast Feeding -
- Child -
- Colonic Neoplasms - etiology
- Female -
- Fertility - drug effects
- Gastrointestinal Agents - adverse effects Gastrointestinal Agents - contraindications
- Humans -
- Immunocompromised Host -
- Immunosuppression - adverse effects
- Infection - etiology
- Inflammatory Bowel Diseases - complications Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - immunology
- Infliximab -
- Liver Neoplasms - etiology
- Lymphoma - etiology
- Opportunistic Infections - etiology
- Pregnancy -
- Pregnancy Complications -
- Risk Factors -
- Skin Diseases - etiology
- Tumor Necrosis Factor-alpha - antagonists & inhibitors
- Vaccines - adverse effects Vaccines - contraindications
- Find related publications in this database (Keywords)
- Infliximab
- Crohn's disease
- Ulcerative colitis
- IBD
- Safety
- Consensus